Fig. 2: Methylation Status of 11p15 in BWS-WT and nonBWS-WT.
From: Cancer predisposition signaling in Beckwith-Wiedemann Syndrome drives Wilms tumor development
A Sample groupings based on BWS/nonBWS status plus normal-11p15 vs altered-11p15 nonBWS-WT status used in the study. For IC1 and IC2 methylation results, the area between the dashed lines indicates the normal methylation range presented by Gadd et al. from the TARGET cohort, while the thick black lines indicate the normal range of methylation determined by the control kidney samples used in this study. 11p15 methylation levels for BWS-WT, BWS non-tumor (BWS-NT), and control kidneys (C1, C2, C3) at IC1 (B), and IC2 (C). D Individuals PCA plot of the first two principal components (Dim1 and Dim2) for control kidney (C), BWS matched normal kidney (NT), BWS WT (WT), normal-11p15 nonBWS-WT(APT) from Murphy et al. cohort. E Differential methylation profile comparing BWS matched normal kidney (n = 5), BWS-WT (n = 7), altered-11p15 nonBWS-WT (n = 35), and normal-11p15 nonBWS-WT(n = 4) to control kidneys (n = 3) across chromosome 11p15 region. DMR1, the most significant DMR, from both BWS-WT and altered-11p15 nonBWS-WT overlaps the IC1 region on chromosome 11p15.
